Use of angiogenesis inhibitors in tumour treatment

被引：58

作者：

Fayette, M

Soria, JC

Armand, JP

机构：

[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France

[2] Ctr Leon Berard, Dept Med, F-69008 Lyon, France

来源：

EUROPEAN JOURNAL OF CANCER | 2005年 / 41卷 / 08期

关键词：

cancer; angiogenesis; inhibitors; VEGF;

D O I：

10.1016/j.ejca.2005.02.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advances in molecular biology have permitted the characterisation of mechanisms underlying angiogenesis. Angiogenesis is a crucial process in tumour pathogenesis as it sustains malignant cells with nutrients and oxygen. It is well known that tumour cells secrete various growth factors including VEGF, which triggers endothelial cells to form new capillaries. Preventing the expansion of new blood vessel networks results in reduced tumour size and metastases. Not surprisingly, numerous drugs that are currently under clinical development interfere with growth factor-derived angiogenic signals. This review aims to describe angiogenesis inhibitors and surveys their different modes of action. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1109 / 1116

页数：8

共 53 条

[1] Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer [J].

Altorki, NK ;

Keresztes, RS ;

Port, JL ;

Libby, MD ;

Korst, RJ ;

Flieder, DB ;

Ferrara, CA ;

Yankelevitz, DF ;

Subbaramaiah, K ;

Pasmantier, MW ;

Dannenberg, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2645-2650

[2]

BATIST G, 2002, P AN M AM SOC CLIN, V21, pB25

[3] Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy [J].

Bocci, G ;

Francia, G ;

Man, S ;

Lawler, J ;

Kerbel, RS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) :12917-12922

[4]

Browder T, 2000, CANCER RES, V60, P1878

[5] Angiogenesis in health and disease [J].

Carmeliet, P .

NATURE MEDICINE, 2003, 9 (06) :653-660

[6] Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer [J].

Cooney, MM ;

Radivoyevitch, T ;

Dowlati, A ;

Overmoyer, B ;

Levitan, N ;

Robertson, K ;

Levine, SL ;

DeCaro, K ;

Buchter, C ;

Taylor, A ;

Stambler, BS ;

Remick, SC .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :96-100

[7] Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J].

Crombet, T ;

Osorio, M ;

Cruz, T ;

Roca, C ;

del Castillo, R ;

Mon, R ;

Iznaga-Escobar, N ;

Figueredo, R ;

Koropatnick, J ;

Renginfo, E ;

Fernández, E ;

Alvárez, D ;

Torres, O ;

Ramos, M ;

Leonard, I ;

Pérez, R ;

Lage, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1646-1654

[8]

DAHUT WL, 2003, P AN M AM SOC CLIN, V22, P208

[9] Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer [J].

Dannenberg, AJ ;

Altorki, NK ;

Boyle, JO ;

Dang, C ;

Howe, LR ;

Weksler, BB ;

Subbararnaiah, K .

LANCET ONCOLOGY, 2001, 2 (09) :544-551

[10]

DUPONT J, 2003, P AN M AM SOC CLIN, V22, P194

← 1 2 3 4 5 6 →